Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705477 | 0.86 | F10 (0.53) | F10F2KLKB1PLAT | |
| SCHEMBL4757953 | 0.86 | F10 (0.53) | F10F2KLKB1PLAT | |
| SCHEMBL4758892 | 0.85 | F10 (0.53) | F10F2KLKB1PLAT | |
| SCHEMBL4705527 | 0.85 | F10 (0.53) | F10F2KLKB1PLAT | |
| SCHEMBL4756206 | 0.83 | F10 (0.51) | F10F2KLKB1PLAT | |
| SCHEMBL4757533 | 0.82 | F10 (0.60) | F10F2KLKB1PLAT | |
| SCHEMBL4705388 | 0.82 | F10 (0.60) | F10F2KLKB1PLAT | |
| SCHEMBL4704241 | 0.81 | F10 (0.56) | F10F2KLKB1 | |
| SCHEMBL4704284 | 0.81 | F10 (0.57) | F10F2KLKB1PLAT | |
| SCHEMBL4704286 | 0.81 | F10 (0.57) | F10F2KLKB1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | F10 8/4885F2 4/4885KLKB1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.